GeneDx Holdings Corp. Class A (WGS)

Over the past six months, GeneDx's stock has been influenced by several events. In February 2026, Q4 2025 financial results were reported, with revenue narrowly missing estimates but adjusted profitability exceeding forecasts, and 2026 guidance was reaffirmed. Analyst ratings have been mixed, with some downgrades impacting the stock price. The stock has experienced significant volatility, with a notable share price drop in April 2026. Partnerships were announced with Zevra Therapeutics and Komodo Health in March and January 2026, respectively. There has been insider activity, including a large purchase by Director Keith Meister and sales by the CEO and CFO. A CMS decision to raise Medicare Advantage payment rates provided support, while the launch of a competitor's genomics assay weighed on investor sentiment.

GeneDx Holdings Corp. experiences demand seasonality for its products and services. A dip in test volumes during the first quarter of 2025 was attributed to seasonality, severe winter weather, and fewer business days. The company anticipates acceleration in the second half of the year due to new initiatives.

GeneDx Holdings Corp. is a genomics company focused on providing genetic testing services, particularly for pediatric and rare diseases. It operates in the professional, scientific, and technical services sector, specifically in research and development in the physical, engineering, and life sciences, and is categorized under the Healthcare Services industry. The company aims to deliver personalized health insights by translating genomic data into clinical answers, accelerating drug discovery, and improving health system efficiencies. Its services include whole exome and genome sequencing, with test options like XomeDx and GenomeSeqDx. GeneDx also develops an AI-based platform for NGS analysis and has a core asset called GeneDx Infinity™, the world's largest rare disease genomic dataset.

GeneDx Holdings Corp. is headquartered in Stamford, Connecticut, United States. While its primary market is the United States, the company also accommodates international referrals through its global network.

In the past year, GeneDx's brand reputation has seen positive recognition with the CEO being named to the 2026 TIME100 Health List. However, allegations of fraudulent misrepresentation and code stacking from February 2025, which led to a dispute with UnitedHealthcare and a settlement, represent a significant event that impacted the company's reputation. No new similar negative events were found within the past year, beyond investor concerns related to profitability and reimbursement risk.

GeneDx Holdings Corp. has significant institutional ownership, with 292 institutional owners holding a total of 30,592,123 shares. Major institutional owners include Corvex Management LP, Casdin Capital, LLC, and BlackRock, Inc. Individual insider ownership stands at 4.04%, representing 1.18 million shares, with notable activity including Director Keith Meister's open-market purchase in March 2026.